AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Frequency Therapeutics to Present Business and Pipeline Overview at the 38th Annual J.P. Morgan Healthcare Conference

January 7, 2020 GMT

WOBURN, Mass.--(BUSINESS WIRE)--Jan 7, 2020--

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that Chief Executive Officer David L. Lucchino will present a Company overview at the 38 th annual J.P. Morgan Healthcare conference.

Mr. Lucchino’s presentation will take place on Wednesday, January 15 th at 11 a.m. PT (2 p.m. ET) in the Elizabethan A room at the Westin St. Francis Hotel in San Francisco. The presentation will be followed by a question and answer session to be held in the Sussex room at 11:30 a.m. PT (2:30 p.m. ET). A live webcast of the both the presentation and the breakout session can be accessed on the investors section of the Frequency’s website, investors.frequencytx.com, or by linking here. A replay of the presentation will be posted on the Frequency website following the event.

About Frequency Therapeutics

Frequency Therapeutics is a leader in the development of medicines designed to activate progenitor cells within the body to treat degenerative diseases. The Company’s progenitor cell activation (PCA) approach stimulates progenitor cells to create functional tissue with the aim of developing disease modifying therapies. The Company’s lead product candidate, FX-322, is designed to regenerate auditory hair cells to restore hearing function. In a FX-322 Phase 1/2 study, statistically significant and clinically meaningful improvements in key measures of hearing function in patients with sensorineural hearing loss were observed. The Company also is evaluating additional diseases where its PCA approach could create functional tissue, including a development program in multiple sclerosis.

Headquartered in Woburn, Mass., Frequency has a license and collaboration agreement with Astellas Pharma Inc. for FX-322, for which it retains U.S. rights, as well as additional collaboration and licensing agreements with academic and nonprofit research organizations including The Scripps Research Institute, Massachusetts Eye and Ear, Partners Healthcare and the Massachusetts Institute of Technology. For more information, visit www.frequencytx.com and follow Frequency on Twitter @Frequencytx.

View source version on businesswire.com:https://www.businesswire.com/news/home/20200107005231/en/

CONTACT: Investor Contact:

Carlo Tanzi, Ph.D.

Kendall Investor Relations

ctanzi@kendallir.com

617-914-0008Media Contact:

Courtney Heath

Scient Public Relations

courtney@scientpr.com

617-872-2462

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA MASSACHUSETTS

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS PHARMACEUTICAL FDA

SOURCE: Frequency Therapeutics

Copyright Business Wire 2020.

PUB: 01/07/2020 09:00 AM/DISC: 01/07/2020 09:01 AM

http://www.businesswire.com/news/home/20200107005231/en